Precision Biosciences Inc.
A clinical-stage gene editing company whose ARCUS platform, built on a naturally occurring enzyme first found in green algae, develops therapies for chronic hepatitis B and Duchenne muscular dystrophy. Three Duke University postdocs founded the company in 2006 after their lab discovery placed second in a university start-up challenge, and the earliest ARCUS work actually edited crops like corn and soybean before turning to human medicines.
Bought 50.0K
Granted 382.0K · Sold 172.0K
Bought 50.0K
Granted 346.1K · Sold 146.2K
Bought 6.5K
Granted 1.01M · Sold 421.5K
Granted 142.3K
Granted 190.8K · Sold 53.8K
Granted 528.9K · Bought 210.8K · Sold 39.5K
Granted 215.0K · Sold 107.9K
Granted 297.6K · Sold 97.3K
Granted 40.7K · Bought 13.9K
Granted 35.0K · Bought 9.9K
Granted 35.0K · Bought 9.3K
Granted 35.0K · Bought 5.4K
Granted 35.0K
Granted 27.5K
Granted 143.4K · Sold 47.1K
Granted 4.2K
Bought 2.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Adelman Robert J +4 co-filersDirector, 10% owner, 10% owner · 3 transactions | — | 4.27Mas of Apr 2019 | — | 50.0K | — |
| Jantz DerekChief Scientific Officer, Director · 36 transactions | — | 4.06Mas of Jun 2022 | 382.0K | — | 172.0K |
| FMR LLCSee Remark 1 · 3 transactions | — | 3.28Mas of Apr 2019 | — | 50.0K | — |
| Kane Matthew R.President and CEO, Director · 32 transactions | — | 2.02Mas of May 2021 | 346.1K | — | 146.2K |
| Yao Tony Dung LingDirector · 5 transactions | — | 322.9Kas of Apr 2019 | — | 6.5K | — |
| Amoroso MichaelPresident and CEO, Director · 25 transactions | — | 243.4K | 1.01M | — | 421.5K |
| Ansari AbidChief Financial Officer · 7 transactions | — | 144.4Kas of Jun 2020 | 142.3K | — | — |
| Smith J. JeffersonChief Research Officer · 22 transactions | — | 129.9K | 190.8K | — | 53.8K |
| Kelly John AlexanderChief Financial Officer · 35 transactions | — | 125.9K | 528.9K | 210.8K | 39.5K |
| Thomson David S.Chief Operating Officer · 14 transactions | — | 111.5Kas of Jun 2021 | 215.0K | — | 107.9K |
| Scimeca DarioGeneral Counsel and Secretary · 38 transactions | — | 56.5K | 297.6K | — | 97.3K |
| Buehler KevinDirector · 7 transactions | — | 49.1K | 40.7K | 13.9K | — |
| Germano Geno JDirector · 6 transactions | — | 44.9K | 35.0K | 9.9K | — |
| Brown MelindaDirector · 8 transactions | — | 44.3K | 35.0K | 9.3K | — |
| Frankel StanleyDirector · 5 transactions | — | 40.5K | 35.0K | 5.4K | — |
| Schinazi Raymond FDirector · 2 transactions | — | 36.9Kas of Apr 2019 | — | — | — |
| Pire Shari LisaDirector · 3 transactions | — | 35.0K | 35.0K | — | — |
| Barton ShaneVP & Corporate Controller · 6 transactions | — | 27.5Kas of Jun 2023 | 27.5K | — | — |
| List AlanChief Medical Officer · 12 transactions | — | 4.5Kas of May 2024 | 143.4K | — | 47.1K |
| Wadsworth Samuel C.Director · 1 transaction | — | 4.2Kas of May 2024 | 4.2K | — | — |
| Heery ChristopherChief Medical Officer · 2 transactions | — | 250as of Dec 2019 | — | 2.5K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -727.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.